NCT04568603View on ClinicalTrials.gov

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

July 9, 2021

Study Completion Date

July 9, 2021

Conditions
HIV-1 Infection
Interventions
DRUG

Islatravir

ISL 30 mg x 2 (60 mg total) capsules taken by mouth.

Trial Locations (2)

33024

Research Centers of America, LLC ( Site 0002), Hollywood

84124

PRA Health Sciences ( Site 0001), Salt Lake City

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04568603 - Islatravir and Methadone Pharmacokinetics (MK-8591-029) | Biotech Hunter | Biotech Hunter